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Background. Apathy is a very common behavioural and psychological symptom across brain 
disorders. In the last decade, there have been considerable advances in research on apathy and 
motivation. It is thus important to revise the apathy diagnostic criteria published in 2009. The main 
objectives were to: a) revise the definition of apathy; b) update the list of apathy dimensions; c) 
operationalise the diagnostic criteria; and d) suggest appropriate assessment tools including new 
technologies. 
Methods. The expert panel (N=17) included researchers and health care professionals working 
on brain disorders and apathy, a representative of a regulatory body, and a representative of the 
pharmaceutical industry. The revised diagnostic criteria for apathy were developed in a two-step 
process. First, following the standard Delphi methodology, the experts were asked to answer 
questions via web-survey in two rounds. Second, all the collected information was discussed on 
the occasion of the 26th European Congress of Psychiatry held in Nice (France).  
Results. Apathy was defined as a quantitative reduction of goal-directed activity in comparison 
to the patient’s previous level of functioning (criterion A). Symptoms must persist for at least four 
weeks, and affect at least two of the three apathy dimensions (behaviour/cognition; emotion; 
social interaction; criterion B). Apathy should cause identifiable functional impairments (criterion 
C), and should not be fully explained by other factors, such as effects of a substance or major 
changes in the patient’s environment. 
Conclusions. The new diagnostic criteria for apathy provide a clinical and scientific framework to 
increase the validity of apathy as a clinical construct. This should also help to pave the path for 
apathy in brain disorders to be an interventional target. 
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Apathy is a pervasive neuropsychiatric symptom of most neurocognitive, neurodegenerative, and 
psychiatric disorders. It represents the most common behavioural and psychological symptom in 
people with Alzheimer’s disease [1] and Huntington’s disease [2], and is prevalent in other 
neurodegenerative conditions, such as Parkinson’s disease [3] and vascular dementia [4]. It is also 
found among substantial proportions of individuals following stroke and traumatic brain injury [5], 
and psychiatric conditions such as major depressive disorder [6] and schizophrenia [7]. The 
presence of apathy significantly affects the patient’s quality of life [8], and in neurodegenerative 
disorders is associated with a faster cognitive and functional decline [9], representing a risk factor 
for the conversion from mild cognitive impairment to Alzheimer’s disease [10]. For all these 
reasons, identifying apathy early in disease progression is considered a clinical and research 
priority.  
In major contributions [11-14], apathy was defined as a lack of motivation that persists over time 
and causes identifiable functional impairment. Three dimensions of apathy were identified, 
including deficits in goal-directed behaviour, goal-directed cognitive activity, and emotions. In 2008, 
a task force was set up during the European Psychiatric Association congress to develop 
diagnostic criteria for apathy [15]. Based on these diagnostic criteria, a patient is classified as 
apathetic when he/she meets four criteria (A-D). Criterion A specifies the presence of a loss of (or 
diminished) motivation in comparison to the person’s previous level of functioning, which is not 
consistent with his age or culture. These changes in motivation may be reported by the patient 
himself or by the observations of others. Criterion B stipulates the presence of symptoms in at 
least two of three domains (behaviour, cognition, and emotion) for a period of at least four weeks 
and present most of the time. These symptoms can be detected either in self-initiated or 
environment-stimulated activities. Criterion C specifies that the symptoms (A - B) must cause 
clinically significant impairment in personal, social, occupational domains, or other important areas 
of functioning. Finally, Criterion D specifies that the symptoms (A - B) should not exclusively 
explained or due to physical or motor disabilities, to diminished level of consciousness or to the 
direct physiological effects of a substance. 
These diagnostic criteria for apathy are now widely used in clinical and research practice for 
patients with neurodegenerative and neuropsychiatric disorders (e.g., [16]). 
 
In the last decade, there have been considerable advances in the domain of apathy in brain 
disorders, including the apathy biological and neural based (e.g., [17]). First, the definition of 
apathy as a disorder of ‘motivation’ (Criterion A) has been extensively criticized (e.g., [18]), as 
‘motivation’ is a psychological interpretation of behavioural internal states, which may be difficult to 
measure objectively. At the same time, the construct of goal directed behaviour/activity - construed 
as a set of related processes by which an internal state is translated, through observable action, 
into the attainment of a goal (e.g., [19]) - is increasingly used in the domain of neuroscience, and it 
has been proposed to be a useful to operationalize apathy, particularly in clinical contexts. Second, 
the different apathy domains (criterion B) have been object of  discussion, and most particularly:  
a) the distinction between the ‘behaviour’ and ‘cognition’ domains and its relevance  in clinical 
practice [20]; b) the importance of adding the  ‘social interaction’ as a domain of apathy [21]; c) the 
importance of considering alternative proposals on apathy sub-types based on the underlying 
disrupted mechanisms (for instance, the ‘emotional–affective’, ‘cognitive’ and ‘auto-activation’ 
apathy subtypes [18]. Third, finer assessment tools for apathy have been developed, based on 
classical instruments (e.g., interviews and self-reports; see [17] for a review) but also on new 
4 
information and communication technologies (ICTs, e.g., [22]). However, no consensus has been 
reached so far on the role of ICTs in the apathy assessment, and on their relations to classical 
apathy measures.   
Finally, the therapeutic strategy is an important aspect to consider. Despite the lack of an 
established pharmacological treatment for apathy with a strong evidence base (e.g., [23]), 
preliminary data on apathy treatment efficacy are emerging [24], with a research focus on drugs 
[25] and repetitive transcranial magnetic stimulation [26], often accompanied by non-
pharmacological approaches [27]. Having diagnostic criteria for apathy based on the last 
advancements in the clinical research that reach a wide consensus among the scientific, regulatory 
and medical community is therefore crucial. These would, for example, allow clinical trials to be 
designed with a well-defined population and more sensitive apathy outcome measures, and thus 
obtain wider acceptance regarding the effectiveness of prevention and/or treatment strategies.                
  
Given all these advances, a group of experts in the domain of apathy in brain disorders (leaded by 
PR and KL) proposed to revise the diagnostic criteria for apathy proposed in 2008. The main 
objectives were to: a) revise the definition of apathy (criterion A); b) update the list of apathy 
dimensions (criterion B); c) operationalize the diagnostic criteria using examples of clinical 
situations and areas of possible impairment (criterion B); and d) suggest appropriate and updated 
apathy assessment tools.  
2. Methods 
Task force. Participants were selected based on their expertise in the domain of apathy in brain 
disorders. Some of these experts already participated to the 2008 expert meeting. These 
included, among others, clinicians and researchers from a) the CoBTeK-IA lab and Memory 
centre of the University Côte d’Azur, a lab with a focus on how to assess apathy using ICT); b) 
the French Memory Centre network, which includes 17 research memory centres located in the 
French university hospitals, c) the ISCTM (International Society for CNS Clinical Trials and 
Methodology) Apathy Workgroup; d) the ISTAART (International Society to Advance Alzheimer's 
Research and Treatment) Neuropsychiatric symptoms professional Interest Area.  
The final task force included 23 experts (researchers, health care professionals and 
representatives of one regulatory body and of the pharmaceutical industry). The complete list of 
the experts, together with their field of expertise, is reported in Annex.  
Following the standard Delphi methodology [28], the revised diagnostic criteria for apathy were 
developed in a two-step process: web-surveys followed by a consensus meeting.   
Web-surveys. The experts were asked to answer questions via web-survey in two rounds 
(between November 2017 and February 2018). After each round, a facilitator (PR) provided a 
summary of the experts’ responses, and encouraged the experts to analyze, comment and 
(eventually) revise their earlier responses in light of the commentaries of other members of the 
panel. The questions for the second round were designed according to the responses obtained 
in the first round. In addition, between the first and second round, the experts were asked to 
work in subgroups in order to focus on different topics (generate definitions, find relevant 
examples in the clinical practice, indicate the potential to employ new technologies). After the 
second round, a first draft of the new criteria, including the elements of the two rounds and the 
documents provided by the subgroups, were circulated among all the experts. A shortened 
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version of the questionnaire (questions 1 to 4) was also sent to the French Memory Centers 
network, which includes 17 research memory centers located in the French university hospital. 
Responses were obtained from 11 centers (64%). 
Final consensus meeting. The two web-survey results and the open discussion points were 
revised by the task force during the 26th European Congress of Psychiatry held on March 5, 
2018 in Nice (France). A consensus was reached when all participants agreed on the decision to 
modify (or not) specific aspects of the current diagnostic criteria for apathy.   
3. Results  
The new proposed diagnostic criteria for apathy, to be employed both in the clinical and the 
research domain, are reported in Table 1. The list of questions and responses for the two web-
surveys are reported in Annex (responses obtained from 17 participants). 
Title: Diagnostic Criteria for Apathy. No modification was performed to be consistent with the 
previous literature.  
Criterion A. This stipulates the presence of quantitative reduction of goal-directed activity either in 
the behavioural, cognitive, emotional or social dimension in comparison to the patient’s previous 
level of functioning. These changes may be reported by the patient him/herself or by the 
observation of others. 
Modifications: 1) The term ‘motivation’ was replaced by ‘goal-directed behaviour/activity’, which is 
easier to observe and objectively quantify (see [18]). 2) The sentence ‘which is not consistent with 
his/her age or culture’ was removed, as it was considered unnecessary (as apathy is defined as a 
reduction compared to the person’s previous level of functioning); 3) the different apathy 
dimensions were listed in the definition (the behavioural, cognitive, emotional or social 
dimensions), to specify immediately the relevant domains. 
Criterion B. This indicates that apathy is a persistent state, rather than a transient or intermittent 
one by incorporating in the definition a minimum duration of four weeks [30]. It also stipulates that 
symptoms should be observed in at least 2 out of the following 3 dimensions:  
B1. Behaviour & Cognition. This includes the loss of, or diminished, goal-directed behaviour and 
cognitive activity as evidenced by at least one of 5 examples / situations. This domain embeds the 
loss of or diminished goal-directed behaviour, i.e., a reduction in routine (habitual) and non-routine 
(occasional) activities, and a reduced goal-directed cognitive activity, usually interpreted in 
practical terms as a loss of or diminished interests.  
B2. Emotion. This included the loss of, or diminished, emotion as evidenced by at least one of 5 
examples /situations including both spontaneous emotions, and emotions in response to the 
environment/others. 
B3. Social interaction. This refers to the loss of, or diminished engagement in social interaction as 
evidenced by at least one of 5 examples /situations. These include both spontaneous social 
initiative, and environment/others stimulated social interaction.  
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Modifications: 1) the term ‘domains’ was replaced with ‘dimensions’, as there is some overlap 
between behaviour/cognition, emotion and social interaction areas. 2) The apathy dimensions 
were modified (previous dimensions: Cognition; Behavior; Emotion). First, as deficits in ‘Behavior’ 
and ‘Cognition’ were found to be frequently associated in the clinical practice and in large studies 
(e.g., [20])	 it was agreed that these two dimensions could be included in a single category. 
Furthermore, it was agreed that it is important to add the ‘Social interaction’ dimension. The fact 
that impaired social interaction is an important domain of apathy has been previously highlighted 
by Sockeel and colleagues during the development of the LARS scale [30]. There is now 
converging evidence that the social dimension may represent a separate apathy domain, distinct 
from cognition/behaviour and emotion [31-33]. 3) The difference between self-initiated and 
environmentally stimulated deficits was presented in the examples provided for each dimension, 
instead of being part of the main definition. 4) Areas of impairment (five examples per dimension) 
were added. This was considered as important to help clinicians in their everyday practice, and to 
help to operationalize the diagnostic criteria. The examples were drafted by a sub-group of experts 
based on their clinical experience, and validated by all the experts task force. 
Criterion C. This refers to the presence of clinically significant functional impairment (e.g., in 
personal, social and/or occupational domains) largely attributable to the symptoms specified in 
criteria A and B. No modification was performed. 
Criterion D. The intent is to exclude from the definition conditions and states that might not be 
distinguished from apathy solely on the basis of the criteria above (e.g., diminished level of 
consciousness), as well as transient states of apathy that can be attributed to a discrete non-
neuropsychiatric cause (e.g., direct physiological effects of a drug/medication). This criterion also 
suggests taking into account whether major changes in the patient’s environment occurred (e.g., 
severe conflicts, loss of significant people), that might completely explain the observed symptoms. 
Modifications: The following sentence was added “The symptoms (A - B) are not exclusively 
explained or due to major changes in the patient’s environment”. This was decided after 
acknowledging that major environmental events, such as a terrorist attack, may lead to major 
changes in several aspects of everyday life that may mimic apathy (e.g., social isolation, emotional 
blunting, reduction of activities outside).  
Appendices. The appendices (available as well as in the criteria at the following link: http://www.innovation-
alzheimer.fr/wp-content/uploads/downloads/2018/04/Apathy-Criteria-2018.pdf) includes the following elements: 
1) Goal-directed behaviour/activity: This section defines goal-directed behaviour/activity as 
behaviour aimed toward a goal or toward the completion of a task. It also considers the presumed 
pathophysiological mechanisms underpinning apathy as being the consequence of various 
underlying dysfunctions of mental and biological processes required to elaborate, initiate and 
control intentional/goal-directed behaviour).  
2) A summary of the main instruments that can be employed to assess apathy. Specifically, apathy 
can be assessed through: 
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a) A number of clinical scales and indexes (e.g., [16]), based on the patient’s self-reports, and/or 
informant-based scales and indexes, and/or clinician’s scales. Table 3 reports the selected clinical 
scales/indexes available, specifying whether they include a patient, informant and/or clinician 
version; the apathy dimensions that each instrument assesses, and the population for which the 
instrument was initially designed/tested. 
b) New Information and Communication Technologies (ICT). There is emerging evidence that new 
ICT approaches could provide clinicians with valuable additional information in terms of 
assessment, and therefore more accurate diagnosis of apathy (e.g., [22]). For this reason, the 
appendix presents a list of ICT instruments that could be employed to assess different aspects and 
dimensions of apathy. These include: actigraphy and methods used to monitor motor activity and 
rest-activity rhythms (e.g., [35]); voice analysis, video analysis, serious games, and robots, which 
are already developed, but currently employed only in research settings (e.g., [36]). 
Some cautions were also added. For instance, regarding clinical scales, it was reported that, due 
to anosognosia, patient’s reports should be taken with caution. Regarding the caregiver’s reports, it 
is important to select a reliable caregiver (e.g., someone who spends sufficient time with the 
patient, and is able to provide an accurate evaluation) as well as taking into account their potential 
biases. It is possible to use other types of scales / assessment tools in parallel to assess co-
morbidities (e.g., for depression, anxiety, fatigue). Concerning ICT, results should be interpreted 
with caution in patients with movement disorders who may show poverty of movement in the 
absence of apathy (e.g., Parkinson’s disease, Huntington’s disease, progressive supranuclear 
palsy). These patients often have reduced total activity, related to their motor symptoms. Likewise, 
they may speak slowly, with a hypophonic voice, have low speech rates due to speech and 
respiratory deficits; or have a hypomimic face that can give the erroneous impression that they do 
not have emotional reactions.  
3) A summary of what is needed for pharmacological clinical trials. This includes providing: a) the 
scientific rationale (biological basis) for targeting specific dimensions; b) the relation with the 
product intended for development (mechanism of action); c) justification for the selection of clinical 
trial endpoints (see discussion). 
 
4. Discussion 
Recent literature points to the importance of adopting a trans diagnostic approach, which cuts 
across traditional disease boundaries, to provide useful means for better understanding of apathy 
and related conditions (Husain & Roiser, in press). Reaching a wide, international consensus on 
the definition and dimensions of apathy is a crucial step in this direction. The expert panel that 
worked to develop the 2018 diagnostic criteria for apathy involved clinicians working on different 
brain disorders, including Alzheimer’s disease and other neurodegenerative disorders, major 
depression and schizophrenia. Similarly, it involved people from different disciplines, such as adult 
and geriatric psychiatry, neurology, neuropsychopharmacology, informatics and technology as well 
as people from the pharmaceutical industry and from the regulatory domain. For this reason, we 
are convinced that the 2018 apathy criteria may have an impact on the clinical and research 
community. 
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The 2018 apathy diagnostic criteria keep the same overall structure (criteria A-D) compared to the 
previous criteria [15]. However major modifications were performed. Specifically: 
Criterion A: the term motivation was replaced by goal-directed behavior. This was a pragmatic 
choice, because ‘goal-directed behaviors’ are easier to observe and describe compared to 
motivation, which is an internal state that can only be inferred from behaviour observation. This is 
also in line with the recent scientific literature [18]. 
Criterion B: the expert panel faced the challenge of keeping the same 3-dimentions structures. 
This is for pragmatic reasons, as the diagnostic criteria should be easy and fast to assess in the 
clinical practice. At the same time, it was important to include a broader spectrum of symptoms, in 
particular related to the social interaction aspects. This led to add ‘social interaction’ as a separate 
dimension, and for practical and theoretical reasons, to subsume behavioral and cognitive domains 
of apathy under one category. This association could be criticised because the category ‘behavior-
cognition’ is very broad, and puts together symptoms that can potentially be dissociated based on 
the underling brain processes (e.g., [37,38]).  However, in the clinical practice, it is difficult to 
dissociate cognitive from behavioral deficits, because both result in diminished observable activity. 
The revision of the diagnostic criteria is not primarily meant for basic research purposes; it is 
mainly meant to improve the clinical description, and thus the assessment of apathy across brain 
disorders in the domain of clinical research and the everyday clinical practice. In this domain the 
association between ‘behavior’ and ‘cognition’ makes sense. The clinical focus also explains why 
the dimensions included in the present criteria do not totally overlap with the sub-forms of apathy 
described by Levy and Dubois [18], that is the ‘emotional-affective, cognitive’ and 'auto-activation' 
subtypes. That classification relies on potential mechanisms underlying apathy, while the 
classification presented here refers to the dimensions for which impairment can be observed at the 
clinical level. The focus on designing more understandable and easy to use criteria also justifies 
the efforts done for operationalizing each domain with the same number of examples. In the case 
of the B1 dimension, these include both cognitive and behavioral aspects. Furthermore, the 
examples systematically include symptoms related to activity self-initiation, and to activities in 
response to the environment stimulation.  
The validation of these criteria in clinical practice will determine if this 3-dimensions structure is 
meaningful, and which are the most frequent examples found for each dimension.  
As in the previous diagnostic systems, the presence of impairment in at least two dimensions is 
needed to fulfill criterion B. This allows the possibility that some patients with a deficit in a single 
apathy dimension are not classified as apathetic. However, it is important to keep track of these 
single-dimension deficits, most particularly for the early pathologies stages, in order to better 
understand if there is a continuum between single symptoms and apparition of a full apathy 
spectrum. This is of interest in the field of AD and related disorders, but also in other 
neuropsychiatric diseases. 
In parallel to facilitate the ease of use in the clinical practice, one of the major challenges of the 
new criteria is to pave the path for the use of new technologies in the assessment domain. This is 
true for apathy but also for other neuropsychiatric symptoms. The assessment methods will 
improve and become more objective thanks to ICT. This is why the present apathy criteria provide 
symptoms descriptions as objective as possible, and encompassing the overall spectrum of 
symptoms. Today, despite some limitations, the motor activity assessment seems the most robust 
method, as reported in detail in the Appendix (e.g., [39,40]). But, in the next future, emerging 
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technologies such as audio and video sensors could be part of the clinicians’ choice options (e.g., 
[36]). 
 The new criteria should also provide additional elements to inform the choice of non-
pharmacological treatments targeted to a specific patient. For instance, examples were included 
for each dimension to help to indicate if the symptoms concerned spontaneous behavior, or the 
behavior in response to other people or the environment. 
We are convinced that the 2018 apathy diagnostic criteria may also be important to provide more 
objective and internationally recognized criteria for apathy assessment for pharmacological 
therapeutic research. Despite the lack of biological or molecular understanding of many of the 
phenomenological domains in the context of major psychiatric or neurological categories, 
regulatory science is moving towards a dimensional approach to drug targets. Phenomenological 
domains can be described within or across diagnostic entities. In order to accept a 
phenomenological domain as a drug target, a rationale should be provided for the validity of its 
construct and the value for the patients. The new diagnostic criteria for apathy provide a clinical 
and scientific framework to increase the validity and the value of apathy as a clinical construct. 
Since the present revision of the diagnostic criteria considers apathy as a domain that exists 
across clinical diagnoses such as major and mild neurocognitive disorders, schizophrenia and 
major depression, the consistency of the evaluation should be demonstrated independently from 
the population in which the assessment is carried out. As a general regulatory requirement, clinical 
trials designed to test a specific hypothesis of efficacy on apathy in the context of a specific 
diagnostic category are required, as well as adequate endpoints.  Also, depending on whether 
apathy is targeted in the context of dementia, or schizophrenia or major depression, the 
relationship with the time course of the underlying pathology should be established. Adequate 
justification why the product has the potential to improve apathy will be needed. 
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Table 1: Apathy diagnostic criteria 2018  
Apathy diagnostic criteria 2018 
CRITERION A: A quantitative reduction of goal-directed activity either in behavioral, 
cognitive, emotional or social dimensions in comparison to the patient’s previous level 
of functioning in these areas. These changes may be reported by the patient 
himself/herself or by observation of others. 
CRITERION B: The presence of at least 2 of the 3 following dimensions for a period of 
at least four weeks and present most of the time 
B1. BEHAVIOUR & COGNITION                                                                                          
Loss of, or diminished, goal-directed behaviour or cognitive activity as evidenced by at 
least one of the following:  
General level of activity: the patient has a reduced level of activity either at home or work, 
makes less effort to initiate or accomplish tasks spontaneously, or needs to be prompted to 
perform them.  
Persistence of activity: He/she is less persistent in maintaining an activity or conversation, 
finding solutions to problems or thinking of alternative ways to accomplish them if they become 
difficult. 
Making choices: He/she has less interest or takes longer to make choices when different 
alternatives exist (e.g., selecting TV programs, preparing meals, choosing from a menu, etc.)  
Interest in external issue: He/she has less interest in or reacts less to news, either good or 
bad, or has less interest in doing new things 
Personal wellbeing: He/she is less interested in his/her own health and wellbeing or personal 
image (general appearance, grooming, clothes, etc.).                                                                         
B2. EMOTION                                                                                                           
Loss of, or diminished, emotion as evidenced by at least one of the following: 
Spontaneous emotions: the patient shows less spontaneous (self-generated) emotions 
regarding their own affairs, or appears less interested in events that should matter to him/her or 
to people that he/she knows well.                                                                                          
Emotional reactions to environment: He/she expresses less emotional reaction in response 
to positive or negative events in his/her environment that affect him/her or people he/she knows 
well (e.g., when things go well or bad, responding to jokes, or events on a TV program or a 
movie, or when disturbed or prompted to do things he/she would prefer not to do).                                                                                                           
Impact on others: He/she is less concerned about the impact of his/her actions or feelings on 
the people around him/her.                                                                                            
Empathy: He/she shows less empathy to the emotions or feelings of others (e.g., becoming 
happy or sad when someone is happy or sad, or being moved when others need help).                   
Verbal or physical expressions: He/she shows less verbal or physical reactions that reveal 
his/her emotional states. 
B3. SOCIAL INTERACTION                                                                                                                          
Loss of, or diminished engagement in social interaction as evidenced by at least one of 
the following:                                                                                                   
Spontaneous social initiative: the patient takes less initiative in spontaneously proposing 
social or leisure activities to family or others.                                                                                                        
Environmentally stimulated social interaction: He/she participates less, or is less 
comfortable or more indifferent to social or leisure activities suggested by people around him/her                                                                                                                       
Relationship with family members: He/she shows less interest in family members (e.g., to 
know what is happening to them, to meet them or make arrangements to contact them).                                                                  
Verbal interaction: He/she is less likely to initiate a conversation, or he/she withdraws soon 
from it.                                                                                                                          
Homebound: He /She prefer to stays at home more frequently or longer than usual and shows 
less interest in getting out to meet people. 
CRITERION C These symptoms (A - B) cause clinically significant impairment in 
personal, social, occupational, or other important areas of functioning. 
CRITERION D The symptoms (A - B) are not exclusively explained or due to 
physical disabilities (e.g. blindness and loss of hearing), to motor disabilities, to a 
diminished level of consciousness, to the direct physiological effects of a substance 
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